Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQH3906 in systemic lupus erythematosus
CTR20261167Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH3906 in systemic lupus erythematosus (SLE), sponsored by Nanjing Shunxin Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
TQH3906
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261167.